Newsfeeds - Spark Newswire

2 minute read

The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week

Today, 2:45 AM

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news.

AMGN

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 2:45 AM

Gainers

ADTX

1 minute read

News

Aquestive Therapeutics Granted U.S. Patent #11,191,737 ‘Enhanced delivery epinephrine compositions’

By Charles Gross

Today, 2:45 AM

View Patent here

AQST

6 minute read

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates

By Shanthi Rexaline

Today, 2:45 AM

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.

ABBV

1 minute read

Aquestive Therapeutics Q3 EPS $(0.37) Beats $(0.45) Estimate, Sales $13.29M Beat $11.01M Estimate

By Benzinga Newsdesk

Today, 2:45 AM

Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45) by 17.78 percent. This is a 24.49 percent increase over losses of $(0.49) per share

AQST

19 minute read

Earnings Scheduled For November 2, 2021

By Benzinga Insights

Today, 2:45 AM

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.

1 minute read

Watching Shares Of Cybin, Aquestive Therapeutics; Traders Circulate TipRanks Report ‘2 “Strong Buy” Penny Stocks That Could Spike Over 200%’ Mentioning Stocks

By Benzinga Newsdesk

Today, 2:45 AM

https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-could-spike-over-200

AQST

1 minute read

IntelGenx And Aquestive Therapeutics Partner With Leading Men’s Health Company To Market Tadalafil Oral Films In The U.S.

By Benzinga Newsdesk

Today, 2:45 AM

IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction

AQST

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 2:45 AM

ABSI

1 minute read

Earnings

Looking into Aquestive Therapeutics’s Return on Capital Employed

By Benzinga Insights

Today, 2:45 AM

After pulling data from Benzinga Pro it seems like during Q2, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $15.35 million. Despite a 23.55% in earnings, the company posted a loss of $6.52 million.

AQST